HBM Healthcare Investments is a principal investment firm established in 2001 and based in Zug, Switzerland, with a focus on the biotechnology, human medicine, diagnostics, and medical technology sectors. The firm invests globally in approximately 40 mature emerging companies, primarily targeting private firms that demonstrate significant value creation potential. Approximately two-thirds of its portfolio consists of investments in unquoted companies, while the remainder includes public companies and funds. HBM Healthcare Investments has developed a distinctive market position through its strategic investments in firms whose products are either at advanced stages of development or already available in the market. This diversified approach allows the firm to leverage opportunities across Europe, Asia, and North America, contributing to its broad shareholder base and enhancing its investment capabilities.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Sphingotec GmbH is a biopharmaceutical company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of biomarkers aimed at diagnosing, predicting, and monitoring acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating monoclonal antibody therapies combined with targeted diagnostic tests tailored for critically ill patients. These innovations work to neutralize harmful substances in the bloodstream, normalize organ function, and enhance survival rates. Additionally, Sphingotec offers biomarkers that assess kidney and endothelial function in critical conditions, thereby enabling healthcare professionals to improve patient management and accelerate recovery for those with severe health issues.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.
Neuron23, Inc. develops and manufactures medicines for genetic disorders using advanced artificial intelligence technology and genetics. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company focuses on creating therapeutics for neurological diseases, including Parkinson's and Alzheimer's, as well as immunological disorders. By leveraging recent advancements in human genetics alongside its AI-enabled drug discovery and biomarker platforms, Neuron23 aims to provide innovative treatments for patients suffering from these debilitating conditions, enhancing their quality of life through targeted and effective therapies.
Aculys is a pharmaceutical company focused on developing innovative therapeutic medicines, particularly targeting neurological conditions. The company is dedicated to creating treatments for hypersomnia and other debilitating central nervous system disorders, with the goal of improving the quality of life for affected patients. Through its commitment to advancing medical methods, Aculys aims to deliver effective solutions that address unmet needs in the field of neurology.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
1000Farmacie SRL is an Italian company based in Naples that operates an online platform for retail pharmacies. The platform offers a diverse selection of products authorized for online sale, including pharmaceuticals, cosmetics, food supplements, and pet care items, all bearing the CE guarantee mark. By facilitating the purchase of healthcare products from authorized pharmacies, 1000Farmacie enables customers to obtain these items at competitive prices. The company also provides a same-day delivery service to specified locations, enhancing convenience for its users and allowing them to save both time and money.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Swixx Biopharma is a company that represents biopharma organizations in Central and Eastern Europe (CEE). Founded in 2014 and registered in Baar, Switzerland, it aims to take over the roles of subsidiaries or business units for multinational biopharma, over-the-counter (OTC), and medical device companies in regions they choose not to enter or have exited. Swixx operates with fully owned affiliates across multiple countries, including Albania, Bulgaria, Hungary, Poland, and Romania, among others. The company specializes in research-driven pharmaceutical and healthcare services, focusing on areas such as rare diseases, oncology-hematology, specialty medications, and self-medication. By leveraging its expertise, Swixx Biopharma provides comprehensive health treatment solutions tailored to the needs of the CEE market.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.
SK Biopharmaceuticals Co., Ltd. is a South Korean pharmaceutical company focused on the research, discovery, and development of drugs for central nervous system disorders. Founded in 2011 and headquartered in Seongnam, the company is advancing several clinical candidates, including Cenobamate for epilepsy, Solriamfetol for excessive daytime sleepiness, and Carisbamate for Lennox-Gastaut syndrome. Additionally, Relenopride is in Phase 2 trials for a rare neurological disease, while SKL13865, SKL20540, SKL-PSY, and SKL24741 are in various early-phase trials for conditions such as attention deficit/hyperactivity disorder, schizophrenia, bipolar disorder, and epilepsy. SK Biopharmaceuticals aims to become a leading specialty pharmaceutical company by developing innovative therapies for CNS and metabolic disorders, alongside providing specialized pharmaceutical manufacturing services.
Ignis Therapeutics
Series A in 2021
Ignis Therapeutics is a life science company developing innovative therapies in the field of the central nervous system. With a strong commitment to self-discovery and a development strategy to advance the treatment paradigm, Ignis Therapeutics transforms the approach to treating CNS conditions. Ignis Therapeutics is dedicated to developing products that significantly improve the lives of patients while also providing additional therapeutic options for physicians.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology medicines tailored to individual patients. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments, thereby enhancing the effectiveness of drug development. Acrivon's lead program is ACR-368, also known as prexasertib, which is currently in Phase 2 trials. Additionally, the pipeline includes preclinical programs that target critical components of the DNA Damage Response and cell cycle regulation pathways, specifically focusing on proteins such as WEE1 and PKMYT1. By leveraging these innovative approaches, Acrivon aims to improve therapeutic outcomes for cancer patients.
Neuron23, Inc. develops and manufactures medicines for genetic disorders using advanced artificial intelligence technology and genetics. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company focuses on creating therapeutics for neurological diseases, including Parkinson's and Alzheimer's, as well as immunological disorders. By leveraging recent advancements in human genetics alongside its AI-enabled drug discovery and biomarker platforms, Neuron23 aims to provide innovative treatments for patients suffering from these debilitating conditions, enhancing their quality of life through targeted and effective therapies.
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
C Ray Therapeutics
Series A in 2021
C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.
Swixx Biopharma is a company that represents biopharma organizations in Central and Eastern Europe (CEE). Founded in 2014 and registered in Baar, Switzerland, it aims to take over the roles of subsidiaries or business units for multinational biopharma, over-the-counter (OTC), and medical device companies in regions they choose not to enter or have exited. Swixx operates with fully owned affiliates across multiple countries, including Albania, Bulgaria, Hungary, Poland, and Romania, among others. The company specializes in research-driven pharmaceutical and healthcare services, focusing on areas such as rare diseases, oncology-hematology, specialty medications, and self-medication. By leveraging its expertise, Swixx Biopharma provides comprehensive health treatment solutions tailored to the needs of the CEE market.
Numab Therapeutics AG is a biotechnology company based in Wädenswil, Switzerland, founded in 2011. The company specializes in developing antibody-based therapeutics aimed at treating severe diseases, including cancer and chronic inflammation. Numab utilizes a unique plug-and-play platform that enhances the predictability of the drug discovery process, allowing for the efficient creation of multispecific biotherapeutics. Its research pipeline encompasses various therapeutic areas, including inflammatory bowel disease, immuno-oncology, autoimmunity, and inflammation.
Sphingotec GmbH is a biopharmaceutical company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of biomarkers aimed at diagnosing, predicting, and monitoring acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating monoclonal antibody therapies combined with targeted diagnostic tests tailored for critically ill patients. These innovations work to neutralize harmful substances in the bloodstream, normalize organ function, and enhance survival rates. Additionally, Sphingotec offers biomarkers that assess kidney and endothelial function in critical conditions, thereby enabling healthcare professionals to improve patient management and accelerate recovery for those with severe health issues.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.
Shape Memory Medical is a medical device company based in Santa Clara, California, established in 2009. The company specializes in the commercialization of innovative medical devices that utilize shape memory polymer (SMP) materials, originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical targets the peripheral vascular, cardiovascular, and neurovascular markets, focusing on minimally invasive endovascular applications. The company has introduced the first FDA-cleared medical device in the vascular sector that employs SMP technology, enhancing the ability of physicians to deliver improved patient care. With a team experienced in SMP foam technology and medical device commercialization, Shape Memory Medical aims to provide advanced therapeutic solutions in its field.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Neurelis is a specialty pharmaceutical company based in Encinitas, California, that focuses on licensing, developing, and commercializing products for epilepsy and the broader central nervous system (CNS) market. Founded in 2007, the company aims to address unmet medical needs through a differentiated approach that leverages novel technologies. Neurelis specializes in enhancing drug delivery systems to improve therapeutic benefits across a variety of molecules, including therapeutic proteins, peptides, and non-peptide compounds. By applying its expertise in neuroscience, Neurelis seeks to improve patient care and outcomes for individuals affected by epilepsy and other CNS disorders.
ValCare, Inc. is a medical device company established in 2012 and headquartered in Irvine, California. The company specializes in the design and development of devices and accessories aimed at the minimally invasive treatment of heart valve disease, specifically targeting conditions such as mitral and tricuspid regurgitation. ValCare's innovative technology functions as a docking station for replacement prostheses and provides tools for mitral annulus repair, facilitating advanced treatment options for patients with heart disorders. This approach aims to enhance patient recovery times and improve overall health outcomes.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.
Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Instil Bio is a clinical-stage biotechnology company specializing in the development and commercialization of tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company utilizes a patient's own T cells, harvested from their tumor, which are expanded and reinfused to effectively target and destroy cancer cells. Founded in 2018 and headquartered in Dallas, Texas, Instil Bio is advancing a pipeline of TIL therapies, including ITIL-306, which incorporates a novel genetically engineered approach through its Co-Stimulatory Antigen Receptor (CoStAR) platform. This innovative therapy aims to recognize tumor-associated antigens present in various solid tumors, such as ovarian, uterine, non-small cell lung, and renal cancers. The company is engaged in clinical trials and is supported by a team of experts in cell therapy and significant institutional investment. Additionally, Instil Bio has manufacturing and research facilities in the greater Los Angeles area and Manchester, UK.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
Neuron23, Inc. develops and manufactures medicines for genetic disorders using advanced artificial intelligence technology and genetics. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company focuses on creating therapeutics for neurological diseases, including Parkinson's and Alzheimer's, as well as immunological disorders. By leveraging recent advancements in human genetics alongside its AI-enabled drug discovery and biomarker platforms, Neuron23 aims to provide innovative treatments for patients suffering from these debilitating conditions, enhancing their quality of life through targeted and effective therapies.
NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Swixx Biopharma is a company that represents biopharma organizations in Central and Eastern Europe (CEE). Founded in 2014 and registered in Baar, Switzerland, it aims to take over the roles of subsidiaries or business units for multinational biopharma, over-the-counter (OTC), and medical device companies in regions they choose not to enter or have exited. Swixx operates with fully owned affiliates across multiple countries, including Albania, Bulgaria, Hungary, Poland, and Romania, among others. The company specializes in research-driven pharmaceutical and healthcare services, focusing on areas such as rare diseases, oncology-hematology, specialty medications, and self-medication. By leveraging its expertise, Swixx Biopharma provides comprehensive health treatment solutions tailored to the needs of the CEE market.
Ambrx is a biopharmaceutical company headquartered in La Jolla, California, that specializes in developing engineered precision biologics using a proprietary technology platform to incorporate synthetic amino acids into proteins. The company focuses on creating protein therapeutics that enhance potency, reduce dosing frequency, and improve drug homogeneity. Its development pipeline includes antibody drug conjugates (ADCs), bi-specific product candidates, and long-acting protein therapeutics, alongside various early-stage programs. Ambrx has established collaborations with MabSpace Biosciences for ADC development in oncology, BeiGene for the commercialization of biologic drugs, and NovoCodex Biopharmaceuticals for the advancement of ARX305, an ADC targeting CD70 positive cancers. Founded in 2003, the company aims to innovate and expand the capabilities of biologic therapies.
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
Neuron23, Inc. develops and manufactures medicines for genetic disorders using advanced artificial intelligence technology and genetics. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company focuses on creating therapeutics for neurological diseases, including Parkinson's and Alzheimer's, as well as immunological disorders. By leveraging recent advancements in human genetics alongside its AI-enabled drug discovery and biomarker platforms, Neuron23 aims to provide innovative treatments for patients suffering from these debilitating conditions, enhancing their quality of life through targeted and effective therapies.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Neurelis is a specialty pharmaceutical company based in Encinitas, California, that focuses on licensing, developing, and commercializing products for epilepsy and the broader central nervous system (CNS) market. Founded in 2007, the company aims to address unmet medical needs through a differentiated approach that leverages novel technologies. Neurelis specializes in enhancing drug delivery systems to improve therapeutic benefits across a variety of molecules, including therapeutic proteins, peptides, and non-peptide compounds. By applying its expertise in neuroscience, Neurelis seeks to improve patient care and outcomes for individuals affected by epilepsy and other CNS disorders.
BioShin Limited is a clinical-stage biopharmaceutical company based in Pudong, China, focused on developing innovative medicines and therapies for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018, BioShin operates as a wholly-owned subsidiary of Biohaven Pharmaceutical Holding Company. The company is engaged in advancing clinical trials for various therapeutic approaches, including calcitonin gene-related peptide (CGRP) receptor antagonism aimed at treating migraine and pain, glutamate modulation targeting Alzheimer’s disease and anxiety disorders, and myeloperoxidase (MPO) inhibition to address inflammation and neurodegeneration. With a commitment to the Asia-Pacific region, BioShin leverages expertise from both global industry and academic settings to develop its late-stage product candidates.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Sphingotec GmbH is a biopharmaceutical company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of biomarkers aimed at diagnosing, predicting, and monitoring acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating monoclonal antibody therapies combined with targeted diagnostic tests tailored for critically ill patients. These innovations work to neutralize harmful substances in the bloodstream, normalize organ function, and enhance survival rates. Additionally, Sphingotec offers biomarkers that assess kidney and endothelial function in critical conditions, thereby enabling healthcare professionals to improve patient management and accelerate recovery for those with severe health issues.
Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.
Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.
Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.
Guangdong Jianke Pharmaceutical Co., Ltd. owns and operates nine pharmacy stores in China. The company also operates an online pharmacy retail store. It offers hepatobiliary, dermatology, pediatric, and urology medicines; female medication; medicines for digestive system, nervous system, and respiratory system; nourishing health care products; medical instruments; and beauty care products. The company was founded in 2006 and is based in Dongguan, China.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Shape Memory Medical is a medical device company based in Santa Clara, California, established in 2009. The company specializes in the commercialization of innovative medical devices that utilize shape memory polymer (SMP) materials, originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical targets the peripheral vascular, cardiovascular, and neurovascular markets, focusing on minimally invasive endovascular applications. The company has introduced the first FDA-cleared medical device in the vascular sector that employs SMP technology, enhancing the ability of physicians to deliver improved patient care. With a team experienced in SMP foam technology and medical device commercialization, Shape Memory Medical aims to provide advanced therapeutic solutions in its field.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
Genalyte, Inc. is a clinical and diagnostic life science company based in San Diego, California, specializing in rapid diagnostic testing solutions. Founded in 2007, Genalyte has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify biomolecular interactions, such as those between antibodies and proteins. This platform, known as the Maverick, allows for the direct measurement of protein binding and nucleic acid hybridization. Genalyte's technology is employed by healthcare providers, pharmaceutical companies, and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and test for infectious agents, including Ebola. The company aims to enhance patient care by enabling rapid diagnostics, with tests typically completed in under thirty minutes, and providing mobile laboratory solutions for real-time diagnostics.
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Swixx Biopharma is a company that represents biopharma organizations in Central and Eastern Europe (CEE). Founded in 2014 and registered in Baar, Switzerland, it aims to take over the roles of subsidiaries or business units for multinational biopharma, over-the-counter (OTC), and medical device companies in regions they choose not to enter or have exited. Swixx operates with fully owned affiliates across multiple countries, including Albania, Bulgaria, Hungary, Poland, and Romania, among others. The company specializes in research-driven pharmaceutical and healthcare services, focusing on areas such as rare diseases, oncology-hematology, specialty medications, and self-medication. By leveraging its expertise, Swixx Biopharma provides comprehensive health treatment solutions tailored to the needs of the CEE market.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
MicroOptx, Inc. is a medical device company based in Maple Grove, Minnesota, founded in 2014. It specializes in developing innovative solutions for the treatment of glaucoma, focusing on minimizing intraocular pressure to prevent blindness. The company's flagship product, the Beacon Aqueous Microshunt (BAM), effectively shunts aqueous humor from the anterior chamber to the surface of the eye. Additionally, MicroOptx produces SalVO, a minimally invasive glaucoma surgery micro implant designed for veterinary use. By combining expertise in bioengineering, surgical techniques, and advanced manufacturing, MicroOptx aims to transform glaucoma treatment through its platform technology. The company is committed to addressing this progressive disease, guided by a leadership team with extensive experience in the medical and financial sectors.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on developing treatments for severe inflammation and autoimmune diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, aimed at treating conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. The company is also advancing additional candidates, including VIB4920 for kidney transplantation rejection and Sjögren’s syndrome, as well as VIB7734 for cutaneous lupus erythematosus. Viela Bio has formed a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, the company is dedicated to addressing unmet medical needs in the field of autoimmune disorders.
Cathay Biotech is a leading global company based in Shanghai, China, specializing in synthetic biology and bio-manufacturing to produce sustainable materials from renewable sources. The firm focuses on developing long-chain dibasic acids and bio-based pentamethylene diamine, positioning itself as the first commercial producer of pentanediamine from renewable materials. These innovations enable the production of unique polyamides, which are utilized in engineering polymers and textiles, thereby offering environmentally friendly alternatives to traditional chemical processes. The company's bio-production technique employs biomass and other raw materials under mild conditions, significantly reducing environmental impact and enhancing economic efficiency. Cathay Biotech aims to mitigate the reliance on conventional chemicals while addressing related environmental and safety concerns. The company operates research and development facilities in Zhangjiang Hi-Tech Park, Shanghai, and has production sites in Jinxiang and Wusu, both located in Shandong and Xinjiang provinces, respectively.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for underserved patient populations affected by rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company’s lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III trials for treating desmoid tumors. Other significant candidates include mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for relapsed or refractory multiple myeloma. The company is also exploring additional therapies, such as BGB-3245, an investigational oral inhibitor targeting BRAF mutations, currently in Phase I trials. SpringWorks has established collaborations with several biotechnology and pharmaceutical firms to enhance its research and development efforts.
NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.
Sai Life Sciences Ltd. specializes in the discovery, contract development, and manufacturing of pharmaceuticals for clients in the biotechnology and pharmaceutical sectors. The company offers a comprehensive range of services, including discovery solutions such as synthetic and medicinal chemistry, toxicology, and pharmacology, as well as development services like analytical method validation, stability studies, and formulation development. Additionally, Sai Life Sciences provides manufacturing capabilities for late-phase and commercial products, along with technology transfer services. With a presence in key markets including India, the United States, the European Union, and Japan, the company has established research and manufacturing facilities in Hyderabad, Pune, Bidar, Cambridge, and Manchester. Founded in 1999 and formerly known as SAI Advantium Pharma Limited, Sai Life Sciences is focused on helping its clients accelerate the development of innovative medicines while minimizing risks and costs.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.